Seagen Requests Director Review Of Unpatentability Decision In Adcetris Xae Patent Pgr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

On February 14, 2024, Seagen requested director review of the PTAB's January 16th Final Written Decision ("FWD") in PGR2021-00030 finding antibody-drug conjugate claims in U.S. Patent No. 10,808,039.

April breyer menonSeagen adcetrisFinal written decisionFinal written decision findingSeagen requests director review of unpatentability decision in adcetris xae patent pgrIntellectual property